Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7911360 | 0.88 | NPC1 (0.32) | NPC1ALDH1A1MAPTKDM1AMAOB | |
| SCHEMBL7903011 | 0.82 | ALDH1A1 (0.39) | NPC1ALDH1A1MAPTLMNAALOX12 | |
| SCHEMBL7916779 | 0.81 | — | — | |
| SCHEMBL7912936 | 0.81 | ADRA2A (0.45) | NPC1ALDH1A1MAPTSMN1; SMN2CYP11B2 | |
| SCHEMBL7916798 | 0.80 | ADRA2A (0.44) | NPC1ALDH1A1MAPTSMN1; SMN2CYP11B2 | |
| SCHEMBL7903016 | 0.80 | ADRA2A (0.44) | NPC1ALDH1A1MAPTSMN1; SMN2CYP11B2 | |
| SCHEMBL7902769 | 0.78 | ALDH1A1 (0.37) | NPC1ALDH1A1MAPTLMNAALOX12 | |
| Dimethylamine SCHEMBL7911323 | 0.78 | ADRA2A (0.42) | NPC1ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL7910325 | 0.78 | GRM5 (0.36) | NPC1ALDH1A1MAPTSMN1; SMN2CYP11B2 | |
| SCHEMBL7916701 | 0.75 | NPC1 (0.39) | NPC1ALDH1A1MAPTLMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875625-B2 | 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylmethyl hydrogen sulfate, inhibitory effect on an Na+/H+ exchanger; | TOA EIYO LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | TOA EIYO LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-6258829-B1 | ANTIARRTHMIA AGENTS AND CARDIOVASCULAR DISORDERS | TOA EIYO LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0972767-A1 | CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME | TOA EIYO LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | SLC10A6, SLC26A3, SLC9A3 | NPC1 188/4885ALDH1A1 438/4885MAPT 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.